Talking About Tumors with Ryann and Ryan - A medical oncology podcast

1. Anti-HER2 agent classes
2. Cleopatra Trial
3. Later line options
4. Leptomeningeal carcinomatosis 

Citations

As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com.  We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice.

DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015.

Uptodate.com Waltham, MA: Wolters Kluwer.

Some highlighted references recommended to read related to this specific episode:

1.          Dawood S et al. NEJM. 2001;344(11):783-792. doi:10.1056/NEJM200103153441101

3.          Baselga J et al. NEJM. 2012;366(2):109-119. doi:10.1056/NEJMOA1113216/

4.          Swain SM et al. NEJM. 2015;372(8):724-734. doi:10.1056/NEJMOA1413513/

5.          Verma S  et al. T. NEJM. 2012;367(19):1783-1791. doi:10.1056/NEJMOA1209124/

6.          Cortés J et al. NEJM. 2022;386(12):1143-1154. doi:10.1056/NEJMOA2115022/

7.          Krop IE et al. Lancet Oncol. 2017;18(6):743-754. doi:10.1016/S1470-2045(17)30313-3

8.          Murthy RK et al. NEJM. 2020;382(7):597-609. doi:10.1056/NEJMOA1914609/

Disclosures

Talking about Tumors with Ryan and Ryann is not medical advice.  We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose.  All opinions are those of whoever stated them.  We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic. 

Tags

Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology

1. HER-2 Testing Algorithm
2. Trastuzumab Deruxtecan in HER-2 Low MBC
3. 2:1 Randomization, Treatment of Provider Choice
4. Sacutuzumab Govetacan for later line TNBC and HR positive MBC

Citations

As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com.  We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice.

DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015.

Uptodate.com Waltham, MA: Wolters Kluwer.

Some highlighted references recommended to read related to this specific episode:

1.Wolff A et al. JCO. 2018;36(20):2105-2122. doi:10.1200/JCO.2018.77.8738

2.Modi S et al. NEJM. 2022;387(1):9-20. doi:10.1056/NEJMOA2203690/

3.BardiaI A et al. NEJM. 2021;384:1529-1541. doi:10.1056/NEJMOA2028485

4.Rugo H et al.  JCO. Published online Aug 26, 2022 . doi:10.1200/JCO.22.01002

5.Rugo H et al. Ann Oncol. 2022;33(suppl_7):S808-S869. doi:10.1016/annonc/annonc1089

Disclosures

Talking about Tumors with Ryan and Ryann is not medical advice.  We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose.  All opinions are those of whoever stated them.  We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic. 

Tags

Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology

Thanks to Feed Spot for recognition as one of the best oncology podcasts!
https://blog.feedspot.com/oncology_podcasts/

1.       Endocrine Resistance: Definition and Mechanism

2.       Role of AI with and without CDK4/6 inhibitors

3.       Later line management of metastatic disease

4.       Informative Censoring and the BOLERO-2 trial

Citations

As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com.  We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice.

DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015.

Uptodate.com Waltham, MA: Wolters Kluwer.

Some highlighted references recommended to read related to this specific episode:

1.           Tannock I et al. Ann Oncol. 2020;31(3):331-333. doi:10.1016/J.ANNONC.2019.11.017

2.           André F et al. NEJM. 2019;380(20):1929-1940. doi:10.1056/NEJMOA1813904/

3.           Tannock IF et al.. Annals of Oncology. 2014;25(10):2096. doi:10.1093/annonc/mdu371

4.           Piccart M et al.  Ann Oncol. 2014;25(12):2357-2362. doi:10.1093/ANNONC/MDU456

5.           Baselga J et al. NEJM. 2012;366(6):520-529. doi:10.1056/NEJMOA1109653

6.           Gao JJ et al. Lancet Oncol. 2020;21(2):250-260. doi:10.1016/S1470-2045(19)30804-6

7.           Howie LJ et al. JCO. 2019;37(36):3475-3483. doi:10.1200/JCO.18.02217

8.           Im SA  et al. NEJM. 2019;381(4):307-316. doi:10.1056/NEJMOA1903765/

9.           Hortobagyi GN  et al. NEJM. 2022;386(10):942-950. doi:10.1056/NEJMOA2114663/

10.        Finn RS  et al. NEJM. 2016;375(20):1925-1936. doi:10.1056/NEJMOA1607303/

11.        Turner NC et al. NEJM. 2018;379(20):1926-1936. doi:10.1056/NEJMOA1810527/

12.        Robertson JFR  et al. Lancet. 2016;388(10063):2997-3005. doi:10.1016/S0140-6736(16)32389-3

13.        Mauri D et al.   J Natl Cancer Inst. 2006;98(18):1285-1291. doi:10.1093/JNCI/DJJ357

14.        Lindström LS et al. JCO. 2012;30(21):2601-2608. doi:10.1200/JCO.2011.37.2482

15.        Mouridsen H et al. JCO. 2001;19(10):2596-2606. doi:10.1200/JCO.2001.19.10.2596

Disclosures

Talking about Tumors with Ryan and Ryann is not medical advice.  We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose.  All opinions are those of whoever stated them.  We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic. 

Tags

Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology

1.       Recurrence Risk Scores

2.       TailorRx, RxPonder, MINDACT Trials Overview

3.       Introduction to CDK 4/6 inhibitors

4.       PALLAS and MONARCH-E Discussion

Citations

As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com.  We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice.

DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015.

Uptodate.com Waltham, MA: Wolters Kluwer.

Some highlighted references recommended to read related to this specific episode:

1.           Johnston SRD et al.  JCO. 2020;38(34):3987-3998. doi:10.1200/JCO.20.02514

2.           Harbeck N et al.  Ann Oncol. 2021;32(12):1571-1581. doi:10.1016/J.ANNONC.2021.09.015

3.           Mayer EL et al. Lancet Oncol. 2021;22(2):212-222. doi:10.1016/S1470-2045(20)30642-2

4.           Cardoso F et al. NEJM. 2016;375(8):717-729. doi:10.1056/NEJMOA1602253

5.           Kalinsky K et al.  NEJM. 2021;385(25):2336-2347. doi:10.1056/NEJMOA2108873/

6.           Sparano JA et al.  NEJM. 2019;380(25):2395-2405. doi:10.1056/NEJMOA1904819/

7.           Paik S et al. JCO. 2006;24(23):3726-3734. doi:10.1200/JCO.2005.04.7985

Disclosures

Talking about Tumors with Ryan and Ryann is not medical advice.  We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose.  All opinions are those of whoever stated them.  We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic. 

Tags

Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology

1.       Tamoxifen, its development, mechanism and benefits

2.       Aromatase inhibitors and their benefit in post-menopausal state

3.       Nuances on extended endocrine therapy beyond 5 years

4.       SOFT/TEXT, a broad overview of a complex publication

Citations

As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com.  We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice.

DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015.

Uptodate.com Waltham, MA: Wolters Kluwer.

Some highlighted references on this topic:

1.           Pagani O et al.. NEJM. 2014;371(2):107-118. doi:10.1056/NEJMOA1404037

2.           Francis PA et al. NEJM. 2018;379(2):122-137. doi:10.1056/NEJMOA1803164/

3.           Gnant M et al.  NEJM. 2021;385(5):395-405. doi:10.1056/NEJMOA2104162/

4.           Cuzick J et al. Lancet Oncol. 2010;11(12):1135-1141. doi:10.1016/S1470-2045(10)70257-6

5.           Regan MM  et al. Lancet Oncol. 2011;12(12):1101-1108. doi:10.1016/S1470-2045(11)70270-4

6.           Davies C et al.. The Lancet. 2013;381(9869):805-816. doi:10.1016/S0140-6736(12)61963-1

7.           Goss PE  et al.  NEJM. 2016;375(3):209-219. doi:10.1056/NEJMOA1604700/

8.           Goss PE et al. J Natl Cancer Inst. 2005;97(17):1262-1271. doi:10.1093/JNCI/DJI250

9.           Abe O  et al.   The Lancet. 2011;378(9793):771-784. doi:10.1016/S0140-6736(11)60993-8

10.        Jordan VC. A  Breast Cancer Research. 2003;5(6):294. doi:10.1186/BCR656

Disclosures

Talking about Tumors with Ryan and Ryann is not medical advice.  We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose.  All opinions are those of whoever stated them.  We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic. 

Tags

Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology

1.       First, second, and third generation chemotherapy regimens

2.       Considerations for anthracyclines 

3.       Considerations for taxanes

4.       Adjuvant bisphosphonates

Citations

As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com.  We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice.

DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015.

Uptodate.com Waltham, MA: Wolters Kluwer.

Some highlighted references recommended to read related to this specific episode:

1.           Budd GT et al. J Clin Oncol. 2015;33(1):58-64. doi:10.1200/JCO.2014.56.3296

2.           Citron ML et al. J Clin Oncol. 2003;21(8):1431-1439. doi:10.1200/JCO.2003.09.081

3.           Anampa J, Makower D, Sparano JA. BMC Med. 2015;13(1). doi:10.1186/S12916-015-0439-8

4.           Sparano JA et al. J Clin Oncol. 2015;33(21):2353-2360. doi:10.1200/JCO.2015.60.9271

5.           Coleman R et al. Lancet. 2015;386(10001):1353-1361. doi:10.1016/S0140-6736(15)60908-4

6.           Gray R et al. Lancet. 2019;393(10179):1440-1452. doi:10.1016/S0140-6736(18)33137-4

7.           Abe O et al. Lancet. 2005;365(9472):1687-1717. doi:10.1016/S0140-6736(05)66544-0

8.           Albain K et al. Lancet. 2012;379(9814):432. doi:10.1016/S0140-6736(11)61625-5

Disclosures

Talking about Tumors with Ryan and Ryann is not medical advice.  We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose.  All opinions are those of whoever stated them.  We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic. 

Tags

Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology

1.       History of surgery and radiation for breast cancer

2.       Indication and goal of adjuvant systemic therapy (incl cell-kill hypothesis)

3.       Overview of breast cancer subtypes

4.       Strategies and guidelines for surveillance

Citations

As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com.  We highly encourage review of guidelines published by ASCO, ESMO and other organizations at your region of training.

DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015.

Uptodate.com Waltham, MA: Wolters Kluwer.

Some highlighted references recommended to read related to this specific episode:

1.          Bonadonna G,  et al. N Engl J Med. 1976;294(8):405-410. doi:10.1056/NEJM197602192940801

2.          Giuliano AE, et al.   JAMA. 2017;318(10):918-926. doi:10.1001/JAMA.2017.11470

3.          Abe O et al. Lancet. 2005;365(9472):1687-1717. doi:10.1016/S0140-6736(05)66544-0

4.          Albain K  et al. The Lancet. 2012;379(9814):432-444. doi:10.1016/S0140-6736(11)61625-5

5.          Asselain B et al. Lancet Oncol. 2018;19(1):27-39. doi:10.1016/S1470-2045(17)30777-5

6.          Predict Breast. Accessed September 25, 2022. https://breast.predict.nhs.uk/

7.          Masuda N et al.  NEJM. 2017;376(22):2147-2159. doi:10.1056/NEJMOA1612645

8.          Berruti A et al J Clin Oncol. 2014;32(34):3883-3891. doi:10.1200/JCO.2014.55.2836

9.          von Minckwitz G et al.  J Clin Oncol. 2012;30(15):1796-1804. doi:10.1200/JCO.2011.38.8595

10.        Henry NL et al.  J Clin Oncol. 2019;37(22):1965-1977. doi:10.1200/JCO.19.00948

11.        von Minckwitz G et al. NEJM. 2019;380(7):617-628. doi:10.1056/NEJMOA1814017/

12.        Mukherjee Siddhartha. The emperor of all maladies : a biography of cancer. Published 2010.

13.        Harris LN et al.  J Clin Oncol. 2016;34(10):1134-1150. doi:10.1200/JCO.2015.65.2289

Disclosures

Talking about Tumors with Ryan and Ryann is not medical advice.  We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose.  All opinions are those of whoever stated them.  We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic. 

Tags

Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology

1.       Overview of disease site

2.       Management of localized disease

3.       Surveillance

4.       Metastatic Disease

Citations

As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com

DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015.

Uptodate.com Waltham, MA: Wolters Kluwer.

Some highlighted references recommended to read related to this specific episode:

1.          Rao S, Guren MG, Khan K, et al. Anal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up☆. Annals of Oncology. 2021;32(9):1087-1100. doi:10.1016/j.annonc.2021.06.015

2.          Morris VK, Salem ME, Nimeiri H, et al. Nivolumab for previously treated unresectable metastatic anal cancer (NCI9673): a multicentre, single-arm, phase 2 study. Lancet Oncol. 2017;18(4):446-453. doi:10.1016/S1470-2045(17)30104-3

3.          Rao S, Sclafani F, Eng C, et al. International rare cancers initiative multicenter randomized phase II trial of cisplatin and fluorouracil versus carboplatin and paclitaxel in advanced anal cancer: InterAAct. Journal of Clinical Oncology. 2020;38(22):2510-2518. doi:10.1200/JCO.19.03266

4.          Flam M, John M, Pajak TF, et al. Role of mitomycin in combination with fluorouracil and radiotherapy, and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: results of a phase III randomized intergroup study. https://doi.org/101200/JCO19961492527. 2016;14(9):2527-2539. doi:10.1200/JCO.1996.14.9.2527

5.          James RD, Glynne-Jones R, Meadows HM, et al. Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): A randomised, phase 3, open-label, 2×2 factorial trial. Lancet Oncol. 2013;14(6):516-524. doi:10.1016/S1470-2045(13)70086-X

6.          Northover J, Glynne-Jones R, Sebag-Montefiore D, et al. Chemoradiation for the treatment of epidermoid anal cancer: 13-year follow-up of the first randomised UKCCCR Anal Cancer Trial (ACT I). Br J Cancer. 2010;102(7):1123. doi:10.1038/SJ.BJC.6605605

7.          Nigro ND, Vaitkevicius VK, Considine B. Combined therapy for cancer of the anal canal: A preliminary report. Dis Colon Rectum. 1974;17(3):354-356. doi:10.1007/BF02586980

Disclosures

Talking about Tumors with Ryan and Ryann is not medical advice.  We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose.  All opinions are those of whoever stated them.  We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic. 

Tags

Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology

1.       RAPIDO Trial 

2.       PRODIGE-23 Trial 

3.       OPRA Trial 

4.       Evidence for non-operative potential in MSI-H tumors with immune checkpoint inhibition

Citations

As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com

DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015.

Uptodate.com Waltham, MA: Wolters Kluwer.

Some highlighted references recommended to read related to this specific episode:

1.          Garcia-Aguilar J, et al. Organ. Journal of Clinical Oncology. 2022;18. doi:10.1200/JCO.22.00032

2.          Cercek A  et al. NEJM. 2022;386(25):2363-2376. doi:10.1056/NEJMOA2201445/

3.          July 10, 2020 - EPOV Christopher Hallemeier - The ASCO Post. Accessed August 30, 2022. https://ascopost.com/issues/july-10-2020/epov-christopher-hallemeier/

4.          Thompson H  et al.  J Clin Oncol. 2021;39(15_suppl). doi:10.1200/JCO.2021.39.15_SUPPL.3509

5.          Conroy T et al.  Lancet Oncol. 2021;22(5):702-715. doi:10.1016/S1470-2045(21)00079-6

6.          Bahadoer RR et al. Lancet Oncol. 2021;22(1):29-42. doi:10.1016/S1470-2045(20)30555-6

Disclosures

Talking about Tumors with Ryan and Ryann is not medical advice.  We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose.  All opinions are those of whoever stated them.  We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic. 

1.       Anatomy, definitions, and unique considerations vs colon cancer

2.       Surgical modalities and patterns of failure

3.       Perioperative radiation and chemoradiation

4.       Evidence to support adjuvant systemic therapy

Citations

As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com

DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015.

Uptodate.com Waltham, MA: Wolters Kluwer.

Some highlighted references recommended to read related to this specific episode:

1.          Delitto D et al. JNCI Journal of the National Cancer Institute. 2018;110(5):460. doi:10.1093/JNCI/DJX228

2.          Bujko K et al. Br J Surg. 2006;93(10):1215-1223. doi:10.1002/BJS.5506

3.          Hong YS et al. J Clin Oncol 2018;36(15_suppl):3501  doi:10.1200/JCO.2018.36.15

4.          Hong YS et al. Journal of Clinical Oncology. 2019;37(33):3111-3123. doi:10.1200/JCO.19.00016

5.          Gérard JP  et al.   J Clin Oncol. 2006;24(28):4620-4625. doi:10.1200/JCO.2006.06.7629

6.          Roh MS et al.   J Clin Oncol. 2009;27(31):5124-5130. doi:10.1200/JCO.2009.22.0467

7.          Sauer R et al. NEJM  2004;351(17):1731-1740. doi:10.1056/NEJMOA040694

8.          Erlandsson J et al. Lancet Oncol. 2017;18(3):336-346. doi:10.1016/S1470-2045(17)30086-4

9.          Folkesson J et al. J Clin Oncol. 2005;23(24):5644-5650. doi:10.1200/JCO.2005.08.144

10.        Sebag-Montefiore D et al. Lancet. 2009;373(9666):811-820. doi:10.1016/S0140-6736(09)60484-0

11.        Kapiteijn E et al.  N Engl J Med. 2001;345(9):638-646. doi:10.1056/NEJMOA010580

Disclosures

Talking about Tumors with Ryan and Ryann is not medical advice.  We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose.  All opinions are those of whoever stated them.  We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic. 

Tags

Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology